.svg){kind=small}
Aug-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Where to Buy
Remedy is stocked at 44 licensed dispensaries across Nevada, Oklahoma, and 2 other states, 41 of them in Nevada, with the deepest coverage in Las Vegas, Henderson, Reno, Carson City, and North Las Vegas. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
In August 2026, Remedy’s mix is anchored by Flower at 50.997% share with year-over-year sales down 42.23% and month-over-month down 56.86%, while Vapor Pens hold 28.78% share with year-over-year up 20.77% but month-over-month down 66.03%. Pre-Roll accounts for 7.57% share with year-over-year down 86.94% and month-over-month down 32.48%, contrasted by Edible at 2.66% share with year-over-year up 443.89% and month-over-month up 3925.44%. Concentrates sit at 8.21% share with year-over-year down 47.78% and month-over-month down 47.70%, and Topical at 1.78% share with year-over-year up 184.61% and month-over-month up 41.49%. The pattern implies Remedy is over-weighted to categories with sharp month-over-month declines while its fastest risers are too small to offset the broad contraction, which aligns with an overall brand sales year-over-year decline of 46.50% alongside a 44.27% increase in average price.
These shifts position Remedy as a Flower-led brand facing share and volume risk as its core category experiences a 56.86% month-over-month drop and a 42.23% year-over-year decline, while Edible’s 3925.44% month-over-month and 443.89% year-over-year surge signals an emerging but still subscale growth vector at 2.66% share. Vapor Pens’ contradictory pattern—20.77% year-over-year growth against a 66.03% month-over-month fall—suggests recent distribution or inventory tightening rather than durable demand expansion, and Concentrates’ 47.70% month-over-month decline curtails diversification benefits at 8.21% share. With Flower ranked 56 in Nevada for the category, Remedy’s near-term positioning depends on reallocating toward the growing Edible and Topical niches while stabilizing price architecture, since the 44.27% average price increase has not prevented a 33.27% two-year sales decline.
Competitive Landscape
Remedy sits at rank #56 in NV Flower in August 2026, down 4 positions year over year from #52, while improving 5 spots since May–June to move from #61 three months ago; this divergence from a 33-peak in May 2025 and a current placement outside the top 50 signals a repositioning phase rather than a recovery. Competitive momentum has tightened at the top: STIIIZY climbed from #2 to #1 alongside 50.5% year-over-year sales growth, while RYTHM slipped from #1 to #2 with 4.3% growth, and Neon Moon jumped from #13 to #3 with 159.5% growth; against that backdrop, Remedy’s year-over-year rank decline of 4 positions combined with a 5-position quarter-on-quarter lift implies the brand is stabilizing tactically in the mid-pack but losing relative share to faster-ascending leaders.
Notable Products
Futura Haze (3.5g) posted the steepest decline in August 2026 at -64.8% MoM and slid to rank 6, while Marmalade Infused Pre-Roll (1g) also contracted -59.9% at rank 8, implying a sharp pullback in non-core or experimental formats. At the top, Key Lime Pie (3.5g) held rank 1 despite a -4.8% dip and Wedding Cake (3.5g) rose 12.1% at rank 2, indicating resilience and trading toward familiar Flower strains even as Las Vegas Kush Cake (3.5g) fell -12.1% to rank 3. Four of the top ten are Flower SKUs clustered in ranks 1–4 and 6, with a single Pre-Roll and a lone Vapor Pen at rank 9 accounting for a smaller role, and total dollars remain concentrated in the first three ranks at $36,076 combined. The pattern implies Remedy is consolidating demand around core Flower leaders while pruning or de-emphasizing peripheral SKUs that are not maintaining month-on-month velocity.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
